Congress Bill Could Boost Adial's AUD Therapy Development

Event summary

  • U.S. Congress introduced H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, on March 24, 2026.
  • The bill expands research and development for therapies targeting conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD).
  • H.R. 7091 supports non-abstinence based treatment options aligned with evolving federal policy and definitions of recovery.
  • Adial Pharmaceuticals’ lead candidate, AD04, is a genetically targeted therapy for AUD that aligns with the bill’s focus on harm reduction.

The big picture

The legislation signals a shift in federal policy towards harm reduction in AUD treatment, moving beyond traditional abstinence-only approaches. This change creates a potentially favorable environment for Adial’s AD04, which is specifically designed to address the needs of patients who may not be ready or able to abstain completely. The bill's bipartisan support suggests a degree of political consensus that could accelerate the adoption of new treatment paradigms within the veteran population, a demographic representing a significant unmet need.

What we're watching

Legislative Progress
The bill's progression through the House Committee on Veterans’ Affairs will be critical; amendments or delays could significantly impact Adial’s development timeline and funding prospects.
Clinical Validation
The success of Adial’s planned Phase 3 clinical trial for AD04 will be paramount in demonstrating the efficacy of non-abstinence based therapies and securing broader regulatory support.
Federal Adoption
The extent to which the federal government adopts and implements the updated definition of recovery, including harm reduction strategies, will influence the commercial viability of AD04 and similar therapies.